Blog
Eli Lilly Expands Manufacturing to Meet Mounjaro Demand Surge
Eli Lilly’s diabetes medication Mounjaro has continued to experience robust sales growth despite supply challenges, with the GLP-1/GIP agonist generating ...
Phathom Triumphs with Dual FDA Nods for GERD Therapy Voquezna
Phathom Pharmaceuticals has achieved rapid success with its innovative heartburn medication Voquezna (vonoprazan), securing two FDA approvals in just three ...
Regeneron’s High-Dose Eylea Launch Takes Off, Rivals Roche’s Vabysmo
Roche’s increased sales for its extended-release treatment for macular degeneration, Vabysmo, indicate that consumers are willing to try new therapies. ...
FDA Approves Keytruda for Biliary Cancer, Rivals AstraZeneca’s Imfinzi
Merck’s Keytruda has received FDA approval to treat locally advanced unresectable or metastatic biliary tract cancer, alongside gemcitabine and cisplatin ...
AstraZeneca Buys 22% of Cellectis in Bold Cell, Gene Therapy Venture
AstraZeneca is making a significant move to collaborate with Cellectis, despite Cellectis discontinuing its multiple myeloma CAR-T program just five ...
FDA Panel Approves First CRISPR Therapy After Rigorous Safety Evaluations
The FDA advisory committee has expressed satisfaction with the evaluation of potential off-target effects conducted by CRISPR Therapeutics and Vertex ...
Tonix Pharmaceuticals Abandons Depression Drug Post-Phase 2 Failure
Tonix Pharmaceuticals has experienced a setback in its pipeline as it discontinues the development of a major depression disorder (MDD) ...
C4 Therapeutics Halts Cancer Project Post Phase 1/2 Trial Setback
C4 Therapeutics has made a strategic decision to discontinue the development of CFT8634, an oral BRD9 degrader, following a phase ...
Prelude Focuses on SMARCA in AbCellera Deal and Trims Its Portfolio by Dropping Two Phase 1 Candidates
Prelude Therapeutics is undergoing a strategic shift, significantly streamlining its clinical pipeline to focus on the promising potential of its ...
Rani Therapeutics and Sangamo Cut Staff and Operations to Secure 2024 Viability
Rani Therapeutics and Sangamo Therapeutics are the latest biotech companies to implement substantial workforce reductions as part of their strategies ...
Nurix’s B-cell cancer drug on partial hold by FDA over manufacturing issues
Nurix Therapeutics has temporarily halted a phase 1 trial for its B-cell malignancy drug, NX-2127, as it undertakes a manufacturing ...
Catalent Braces for Potential Revenue Setback Following Sarepta’s Gene Therapy Trial Disappointment
Catalent, having overcome the challenges posed by the pandemic, now faces another potential setback in the form of what analysts ...
Novartis’ Cosentyx Clinches First Approval for Hidradenitis Suppurativa Treatment
Novartis’ Cosentyx has gained an early lead in the field of hidradenitis suppurativa (HS), a painful skin condition, potentially giving ...
Amgen Secures FDA Approval for Stelara Biosimilar, Awaits 2025 Launch Post-Settlement
The FDA has granted approval to Amgen for its biosimilar rendition of Johnson & Johnson’s renowned autoimmune medication, Stelara. However, ...
GSK’s Arexvy Vaccine Poised for Blockbuster Sales, Besting Pfizer in RSV Market Debut
Pfizer is facing not only a decline in its COVID-19 vaccine sales but also stiff competition from GSK in the ...
Genentech’s Alexander Hardy takes over as BioMarin CEO from Jean-Jacques Bienaimé
After an illustrious 18-year tenure, Jean-Jacques Bienaimé, the CEO of BioMarin, is preparing to step down from his role. However, ...
CRISPR-Vertex’s gene editing therapy faces FDA committee review
A significant milestone in the pharmaceutical industry is on the horizon as an FDA advisory committee prepares to review the ...
AbbVie CEO reveals why it passed on Daiichi’s cancer drug
AbbVie CEO Rich Gonzalez has revealed the company’s stance on the recent ADC transaction involving Daiichi and Merck. Despite being ...
ResMed to cut 5% of workforce amid fiscal challenges
As ResMed seizes opportunities in the CPAP machine market, left open due to Philips’ ongoing respiratory device recall issues, the ...
Sanofi’s ‘Play to Win’ strategy backfires, stock tumbles
Sanofi is facing investor discontent as its CEO, Paul Hudson, unveiled the latest chapter in the “Play to Win” strategy ...
Eli Lilly launches Omvoh for ulcerative colitis after FDA nod
Eli Lilly, known for its weight loss contender Mounjaro, is making strides in the immunology arena. The FDA has granted ...
AbbVie writes off $2.1B for Imbruvica amid CMS pricing pressure
The introduction of BeiGene’s groundbreaking oral treatment, Brukinsa, has taken a toll on the sales of AbbVie and Johnson & ...
Novartis accuses ex-employee of stealing confidential files for Takeda
Novartis is pursuing legal action against a former employee from its Egyptian affiliate, who is alleged to have taken thousands ...
Sanofi suffers setbacks for three acquired assets in clinical trials
Sanofi has faced challenges with a trio of therapeutic candidates acquired through its business development endeavors, leading to a pause ...
PTC faces FDA hurdles for two drug candidates, delays filing
PTC Therapeutics finds itself in a regulatory whirlwind, as the latest third-quarter results reveal hurdles and setbacks impacting the biotech’s ...
Novel small molecule blocks breast and ovarian cancer in mice
A groundbreaking discovery in the fight against breast and ovarian cancers has emerged from the laboratories of Baylor College of ...
Menopause poll shows wide range of symptoms and durations
Navigating the menopausal journey is a profoundly individual experience, as diverse as the women who undergo this transformative phase. This ...
Santhera and Catalyst win FDA approval for Duchenne drug Agamree
The FDA’s recent green light for Agamree (vamorolone) in the treatment of Duchenne muscular dystrophy (DMD) has ignited a wave ...
Moderna partners with CEPI to speed up vaccine development for future pandemics
Moderna is teaming up with the Coalition for Epidemic Preparedness Innovations (CEPI) to contribute to the 100 Days Mission, an ...
Roche’s TIGIT Therapy: ESMO Reveals Ongoing Commitment
Roche is taking a steadfast position in the realm of TIGIT-class therapies, even in the face of fluctuating data and ...
